Gardasil 9 Vaccine in Preventing HPV Infection in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

Running, not enrolling · Phase 4

Conditions studied: Allogeneic Hematopoietic Stem Cell Transplant Recipient, Hematopoietic and Lymphoid Cell Neoplasm

In brief

This phase IV trial studies how well Gardasil 9 vaccine works in preventing human papillomavirus (HPV) infection in patients with hematologic malignancies who are undergoing donor stem cell transplant. Vaccines, such as Gardasil 9, may help the body build an effective immune response to kill cancer cells.

Key facts

Study ID

NCT03023631

Run by

M.D. Anderson Cancer Center

People needed

48

Starts

2017-04-23

Expected to finish

2026-09-30

Last updated by the study team

2026-07-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• All English-speaking adult MD Anderson patients with hematologic malignancy at 6-12 months +/- 8 weeks post allogeneic stem cell transplantation who will receive usual post-stem cell transplant vaccinations
• All patients from approved protocol 2015-0795 will be invited to this vaccine study

You may not qualify if…

• Prior allogeneic SCT
• Platelet count less than or equal to 25,000 K/uL
• Absolute neutrophil count less than or equal to 500/uL
• Patients who have ever received HPV vaccination (at least one dose of HPV vaccine)
• Patients with a prior history of HPV-related malignancy
• Female patients who tested positive for pregnancy during pre-SCT evaluation

Where it is running

• M D Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.